[{"id":"1ee70366-b7a8-4f46-abc0-90483806c589","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744652","created_at":"2021-01-18T07:38:47.984Z","updated_at":"2024-07-02T16:35:46.306Z","phase":"Phase 1","brief_title":"Dasatinib and Crizotinib in Advanced Cancer","source_id_and_acronym":"NCT01744652","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • ALK • MET • CDKN2A • DDR2 • CTGF","pipe":" | ","alterations":" BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification","tags":["BRAF • ALK • MET • CDKN2A • DDR2 • CTGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-06-07"},{"id":"125a7b91-8db5-46b8-a5c2-7bd50f1bdda9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05116618","created_at":"2021-11-12T00:10:03.219Z","updated_at":"2024-07-02T16:36:03.722Z","phase":"","brief_title":"Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged","source_id_and_acronym":"NCT05116618","lead_sponsor":"University of Colorado, Denver","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ALK mutation • ROS1 rearrangement • ROS1 mutation • ALK amplification","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ALK mutation • ROS1 rearrangement • ROS1 mutation • ALK amplification"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 09/15/2022","primary_completion_date":" 09/15/2022","study_txt":" Completion: 09/15/2022","study_completion_date":" 09/15/2022","last_update_posted":"2022-09-21"},{"id":"2c723896-04ac-4dd3-8a20-de38e36b8103","acronym":"","url":"https://clinicaltrials.gov/study/NCT00939770","created_at":"2021-01-17T17:10:37.490Z","updated_at":"2024-07-02T16:36:44.430Z","phase":"Phase 1/2","brief_title":"Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT00939770","lead_sponsor":"Children's Oncology Group","biomarkers":" ALK • MET • HGF","pipe":" | ","alterations":" MET amplification • ALK fusion • ALK mutation • MET mutation • ALK amplification","tags":["ALK • MET • HGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • ALK fusion • ALK mutation • MET mutation • ALK amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 09/21/2009","start_date":" 09/21/2009","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2020-06-09"}]